Literature DB >> 28868517

Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.

Nam Bui1, Solomon Henry2, Douglas Wood2, Heather A Wakelee3, Joel W Neal3.   

Abstract

Entities:  

Keywords:  Anaplastic lymphoma kinase; Informatics; Non-small cell lung cancer

Year:  2017        PMID： 28868517      PMCID： PMC5575933          DOI： 10.1200/CCI.16.00055

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN： 2473-4276


× No keyword cloud information.
  7 in total

1.  Meaningful use of electronic health records: the road ahead.

Authors:  Ashish K Jha
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

2.  Rapid-learning system for cancer care.

Authors:  Amy P Abernethy; Lynn M Etheredge; Patricia A Ganz; Paul Wallace; Robert R German; Chalapathy Neti; Peter B Bach; Sharon B Murphy
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

3.  The potential for crizotinib in non-small cell lung cancer: a perspective review.

Authors:  Yung-Jue Bang
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

7.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316
  7 in total
  1 in total

1.  Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  David Hsiehchen; Mary K Watters; Rong Lu; Yang Xie; David E Gerber
Journal:  JAMA Netw Open       Date:  2019-09-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.